miR-181a Targets GATA6 to Inhibit the Progression of Human Laryngeal Squamous Cell Carcinoma

References

• Marioni G , Marchese-RagonaR, CarteiG, MarcheseF, StaffieriA. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat. Rev.32(7), 504–515 (2006).
   PubMed Web of Science ®Google Scholar
• Almadori G , BussuF, CadoniG, GalliJ, PaludettiG, MauriziM. Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinicobiological approach. Eur. J. Cancer41(5), 683–693 (2005).
   PubMed Web of Science ®Google Scholar
• Yu X , WuY, LiuYet al. miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma. Curr. Pharm. Biotechnol.15(5), 503–508 (2014).
   PubMed Web of Science ®Google Scholar
• Hu A , HuangJJ, XuWHet al. miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival. Am. J. Transl. Res.6(5), 604–613 (2014).
   PubMed Web of Science ®Google Scholar
• Liu J , LeiDP, JinT, ZhaoXN, LiG, PanXL. Altered expression of miR-21 and PTEN in human laryngeal and hypopharyngeal squamous cell carcinomas. Asian Pac. J. Cancer Prev.12(10), 2653–2657 (2011).
   PubMedGoogle Scholar
• Wu TY , ZhangTH, QuLMet al. MiR-19a is correlated with prognosis and apoptosis of laryngeal squamous cell carcinoma by regulating TIMP-2 expression. Int. J. Clin. Exp. Pathol.7(1), 56–63 (2014).
   PubMed Web of Science ®Google Scholar
• Brandstorp-Boesen J , FalkRS, BoysenM, BrondboK. Long-term trends in gender, T-stage, subsite and treatment for laryngeal cancer at a single center. Arch. Oto-Rhino-Laryngol.271(12), 3233–3239 (2014).
   Google Scholar
• Suh Y , AmelioI, Guerrero UrbanoT, TavassoliM. Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis.5, e1018 (2014).
   PubMed Web of Science ®Google Scholar
• Chen J , OdenikeO, RowleyJD. Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer10(1), 23–36 (2010).
   PubMed Web of Science ®Google Scholar
• Wu W , SunM, ZouGM, ChenJ. MicroRNA and cancer: current status and prospective. Int. J. Cancer120(5), 953–960 (2007).
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A , SlackFJ. Oncomirs – microRNAs with a role in cancer. Nat. Rev. Cancer6(4), 259–269 (2006).
   PubMed Web of Science ®Google Scholar
• Calin GA , CroceCM. MicroRNA signatures in human cancers. Nat. Rev. Cancer6(11), 857–866 (2006).
   PubMed Web of Science ®Google Scholar
• Lu J , GetzG, MiskaEAet al. MicroRNA expression profiles classify human cancers. Nature435(7043), 834–838 (2005).
   PubMed Web of Science ®Google Scholar
• Guo Y , StricklandSA, MohanSet al. MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. Leuk. Lymphoma58(9), 1–15 (2017).
   Web of Science ®Google Scholar
• Huang P , YeB, YangY, ShiJ, ZhaoH. MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2. Tumor Biol.36(5), 3381–3387 (2015).
   PubMedGoogle Scholar
• Cao Y , ZhaoD, LiPet al. MicroRNA-181a-5p impedes IL-17-induced nonsmall cell lung cancer proliferation and migration through targeting VCAM-1. Cell. Physiol. Biochem.42(1), 346–356 (2017).
   PubMedGoogle Scholar
• Tian F , ShenY, ChenZ, LiR, LuJ, GeQ. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer. Gene591(2), 338–343 (2016).
   PubMed Web of Science ®Google Scholar
• Peng W , SiS, ZhangQet al. Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. J. Exp. Clin. Cancer Res.34, 79 (2015).
   PubMed Web of Science ®Google Scholar
• Strotbek M , SchmidS, Sanchez-GonzalezI, BoerriesM, BuschH, OlayioyeMA. miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer. Int. J. Cancer140(10), 2310–2320 (2017).
   PubMed Web of Science ®Google Scholar
• Tong SJ , LiuJ, WangX, QuLX. microRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression. Exp. Ther. Med.8(4), 1296–1300 (2014).
   PubMed Web of Science ®Google Scholar
• Wang B , HsuSH, MajumderSet al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene29(12), 1787–1797 (2010).
   PubMed Web of Science ®Google Scholar
• Yang CC , HungPS, WangPWet al. miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J. Oral. Pathol. Med.40(5), 397–404 (2011).
   PubMed Web of Science ®Google Scholar
• Liu YS , LinHY, LaiSWet al. MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma. Oncogene36(35), 5006–5022 (2017).
   PubMed Web of Science ®Google Scholar
• Chen Z , WuL, LinQ, ShiJ, LinX, ShiL. Evaluation of miR-182/miR-100 ratio for diagnosis and survival prediction in bladder cancer. Arch. Iran Med.19(9), 645–651 (2016).
   PubMed Web of Science ®Google Scholar
• Pichler M , WinterE, RessALet al. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J. Clin. Pathol.67(3), 198–203 (2014).
   PubMed Web of Science ®Google Scholar
• Kim M , ChenX, ChinLJet al. Extensive sequence variation in the 3′ untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle13(6), 1030–1040 (2014).
   PubMed Web of Science ®Google Scholar
• Molkentin JD . The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J. Biol. Chem.275(50), 38949–38952 (2000).
   PubMed Web of Science ®Google Scholar
• Tian F , ChenJ, ZhengSet al. miR-124 targets GATA6 to suppress cholangiocarcinoma cell invasion and metastasis. BMC Cancer17(1), 175 (2017).
   PubMedGoogle Scholar
• Fantini S , SalsiV, ReggianiL, MaioranaA, ZappavignaV. The miR-196b miRNA inhibits the GATA6 intestinal transcription factor and is upregulated in colon cancer patients. Oncotarget8(3), 4747–4759 (2017).
   PubMedGoogle Scholar
• Ushijima H , HoryozakiA, MaedaM. Anisomycin-induced GATA-6 degradation accompanying a decrease of proliferation of colorectal cancer cell. Biochem. Biophys. Res. Commun.478(1), 481–485 (2016).
   PubMed Web of Science ®Google Scholar
• Shi ZD , LeeK, YangDet al. Genome editing in hPSCs reveals GATA6 haploinsufficiency and a genetic interaction with GATA4 in human pancreatic development. Cell Stem Cell20(5), 675–688, e676 (2017).
   PubMed Web of Science ®Google Scholar
• Martinelli P , Carrillo-de Santa PauE, CoxTet al. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut66(9), 1665–1676 (2017).
   PubMed Web of Science ®Google Scholar
• Song Y , TianT, FuXet al. GATA6 is overexpressed in breast cancer and promotes breast cancer cell epithelial–mesenchymal transition by upregulating slug expression. Exp. Mol. Pathol.99(3), 617–627 (2015).
   PubMed Web of Science ®Google Scholar
• Wu CS , WeiKL, ChouJLet al. Aberrant JAK/STAT signaling suppresses TFF1 and TFF2 through epigenetic silencing of GATA6 in gastric cancer. Int. J. Mol. Sci.17(9), pii: E1467 (2016).
   Web of Science ®Google Scholar
• Zhao XD , JiWY, ZhangWet al. Overexpression of SATB1 in laryngeal squamous cell carcinoma. ORL J. Otorhinolaryngol. Relat. Spec.72(1), 1–5 (2010).
   PubMedGoogle Scholar